3 recruiting, 1 completed, 1 unknown. 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Recruiting 3, Completed 1, Unknown 1 |
Follow ravulizumab: new trials by email Literature Review of ravulizumab trials Research Report on ravulizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD Rituximab (R), Eculizumab (Soliris®), Ravulizumab - NMOSD | Phase 4 | Recruiting | Massachusetts General Hospital | 540 | 2026-09-01 | 2026-09-24 |
| A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone - Generalized Myasthenia Gravis, gMG | Phase 4 | Recruiting | Alexion Pharmaceuticals, Inc. | 75 | 2026-03-04 | 2026-04-09 |
| Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS Ravulizumab - aHUS, Atypical Hemolytic Uremic Syndrome | Phase 4 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2025-12-19 | 2026-04-20 |
| Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab Eculizumab, Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria | Phase 4 | Completed | Alexion Pharmaceuticals, Inc. | 18 | 2021-04-14 | 2024-09-05 |
| mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) Ravulizumab, Baricitinib, Standard of care - COVID19 | Phase 4 | Unknown | Cambridge University Hospitals NHS Foundation Trust | 1167 | 2020-05-08 | 2020-05-18 |
Adrenal Insufficiency (1) · Atypical Hemolytic Uremic Syndrome (1) · COVID-19 (1) · Hemoglobinuria, Paroxysmal (1) · Myasthenia Gravis (1)
Alexion Pharmaceuticals, Inc. (3) · Cambridge University Hospitals NHS Foundation Trust (1) · Massachusetts General Hospital (1)
Germany (2) · Japan (2) · United Kingdom (2) · United States (2) · Italy (1)
Frances Hall Hall, FRCP (UK), D.Phil (1) · Philippe-Antoine Bilodeau, MD (1)
PMID 32641154, PMID 34473343, PMID 37977159
2019 (1)